Linked Life Data

16239764

Source:http://linkedlifedata.com/resource/pubmed/id/16239764

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2005-10-21
pubmed:abstractText
The author s found 6.5-fold reduced nerve growth factor (NGF) levels in the plasma of treated patients with Parkinson disease (PD) compared with healthy control subjects (P = 0.03). A significant positive correlation between levodopa and NGF plasma levels appeared after acute levodopa/benserazide administration. The data suggest that acute levodopa administration may contribute to an increase of NGF plasma concentrations, which are reduced in treated PD patients due to the ongoing disease process itself or chronic antiparkinsonian drug treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0362-5664
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
238-40
pubmed:meshHeading
pubmed:articleTitle
Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.
pubmed:affiliation
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de
pubmed:publicationType
Journal Article, Clinical Trial